COMPOSITION
Each 1 mL of reconstituted solution of menotrophin contains:
| human Follicle stimulating hormone (hFSH). | 75 I.U. |
| human Luteinizing hormone (hLH), approximately | 75 I.U. |
PHARMACOLOGICAL CLASSIFICATION
A/2.1/10/Trophic hormones
PHARMACOLOGICAL ACTION
HUMEGON is a preparation of menotrophin. It contains hFSH and hLH, both of which are necessary for the normal gamete maturation (follicle ripening in the female and spermatogenesis in the male) and for gonadal steroid production.
INDICATIONS
In the female:
| * | Infertility caused by anovulation, associated with hypogonadotrophic hormones and low endogenous estrogen levels; |
| * | Defective follicle ripening and consequent corpus luteum insufficiency, if other treatments have failed. |
| * | Controlled hyperstimulation to increase the number of oocytes available for collection in medically assisted reproduction programs (e.g. In-vitro fertilisation/embryo transfer (IVT/ET) and gamete intrafallopian transfer (GIFT). |
In the male:
| * | Selected cases of deficient spermatogenesis due to inadequate endogenous stimulation of the gonads. |
CONTRA-INDICATIONS:
N.B.:
HUMEGON is not indicated for use in patients, whose blood levels of gonadotrophins and/or prolactin are normal or above normal.
Ovarian, testicular and pituitary tumours.
HUMEGON should not be given to patients with polycystic ovarian disease.
